Mbi 2,000 padi jan\u00eb ngritur kund\u00ebr prodhuesit t\u00eb Ozempic, Novo Nordisk, duke pretenduar se kompania nuk i ka paralajm\u00ebruar n\u00eb m\u00ebnyr\u00eb t\u00eb mjaftueshme p\u00ebrdoruesit dhe mjek\u00ebt p\u00ebr rrezikun e efekteve an\u00ebsore t\u00eb r\u00ebnda. Analist\u00ebt ligjor\u00eb vler\u00ebsojn\u00eb se p\u00ebrgjegj\u00ebsia totale mund t\u00eb kaloj\u00eb 2 miliard\u00eb dollar\u00eb p\u00ebr shkak t\u00eb shkall\u00ebs dhe ashp\u00ebrsis\u00eb s\u00eb l\u00ebndimeve t\u00eb raportuara.<\/p>\n\n\n\n
Akuzat kryesore n\u00eb padi:<\/strong><\/p>\n\n\n\n Gastropareza (paraliza e stomakut): Ky \u00ebsht\u00eb pretendimi m\u00eb i zakonsh\u00ebm n\u00eb padi. \u200b\u200bPadit\u00ebsit pretendojn\u00eb se Ozempic dhe ila\u00e7e t\u00eb tjera t\u00eb ngjashme GLP-1 shkaktojn\u00eb vones\u00eb n\u00eb zbrazjen e stomakut, duke \u00e7uar n\u00eb t\u00eb p\u00ebrziera kronike, t\u00eb vjella, dhimbje barku dhe dehidratim t\u00eb r\u00ebnd\u00eb. Gastropareza \u00ebsht\u00eb shpesh e pash\u00ebrueshme dhe disa pacient\u00eb jan\u00eb shtruar n\u00eb spital dhe kan\u00eb pasur nevoj\u00eb p\u00ebr tuba ushqyerjeje.<\/p>\n\n\n\n Bllokimi i zorr\u00ebve (Ileusi): Padit\u00eb pretendojn\u00eb se ila\u00e7et mund t\u00eb shkaktojn\u00eb nd\u00ebrprerjen e funksionimit t\u00eb duhur t\u00eb zorr\u00ebve, duke \u00e7uar n\u00eb bllokime q\u00eb mund t\u00eb k\u00ebrkojn\u00eb nd\u00ebrhyrje kirurgjikale urgjente. N\u00eb shtator 2023, FDA shtoi nj\u00eb paralajm\u00ebrim p\u00ebr ileus n\u00eb etiket\u00ebn e Ozempic bazuar n\u00eb raportet pas tregtimit.<\/p>\n\n\n\n Humbja e Shikimit (NAION): Nj\u00eb num\u00ebr n\u00eb rritje i padive p\u00ebrfshijn\u00eb pretendime p\u00ebr d\u00ebmtim t\u00eb shikimit, konkretisht Neuropati Optike Iskemike Anteriore Nonarteritike (NAION). Studimet k\u00ebrkimore kan\u00eb treguar nj\u00eb lidhje t\u00eb mundshme midis semaglutid\u00ebs dhe k\u00ebsaj gjendjeje, e cila mund t\u00eb shkaktoj\u00eb humbje t\u00eb papritur dhe t\u00eb pakthyeshme t\u00eb shikimit.<\/p>\n\n\n\n Komplikime t\u00eb tjera: Padit\u00ebsit raportojn\u00eb gjithashtu nj\u00eb s\u00ebr\u00eb problemesh t\u00eb tjera serioze sh\u00ebndet\u00ebsore, duke p\u00ebrfshir\u00eb s\u00ebmundjen e fshik\u00ebz\u00ebs s\u00eb t\u00ebmthit, pankreatitin dhe d\u00ebmtimin e veshkave.<\/p>\n\n\n\n D\u00ebshtimi p\u00ebr t\u00eb paralajm\u00ebruar: Pretendimi kryesor \u00ebsht\u00eb se Novo Nordisk d\u00ebshtoi t\u00eb informonte n\u00eb m\u00ebnyr\u00eb t\u00eb mjaftueshme pacient\u00ebt dhe ofruesit e kujdesit sh\u00ebndet\u00ebsor rreth k\u00ebtyre rreziqeve t\u00eb r\u00ebnda, ve\u00e7an\u00ebrisht nd\u00ebrsa p\u00ebrdorimi jasht\u00eb etiket\u00ebs s\u00eb Ozempic p\u00ebr humbje peshe u rrit. Padit\u00ebsit pretendojn\u00eb se marketingu promovoi p\u00ebrfitimet e ila\u00e7it duke minimizuar ose l\u00ebn\u00eb jasht\u00eb paralajm\u00ebrimet rreth rreziqeve t\u00eb tij t\u00eb mundshme.<\/p>\n","protected":false},"excerpt":{"rendered":" Mbi 2,000 padi jan\u00eb ngritur kund\u00ebr prodhuesit t\u00eb Ozempic, Novo Nordisk, duke pretenduar se kompania nuk i ka paralajm\u00ebruar n\u00eb m\u00ebnyr\u00eb t\u00eb mjaftueshme p\u00ebrdoruesit dhe mjek\u00ebt p\u00ebr rrezikun e efekteve an\u00ebsore t\u00eb r\u00ebnda. Analist\u00ebt ligjor\u00eb vler\u00ebsojn\u00eb se p\u00ebrgjegj\u00ebsia totale mund t\u00eb kaloj\u00eb 2 miliard\u00eb dollar\u00eb p\u00ebr shkak t\u00eb shkall\u00ebs dhe ashp\u00ebrsis\u00eb s\u00eb l\u00ebndimeve t\u00eb raportuara.<\/p>\n","protected":false},"author":4,"featured_media":24674,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[38],"tags":[40],"class_list":{"0":"post-24673","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-tech","8":"tag-featured"},"yoast_head":"\n